Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Portola: Reiterating Buy Prior to June 24th PDUFA Date for Betrixaban (PTLA, Buy, $39.35)

Portola has two drugs in late stage development that I believe are likely to be approved in 2017 or early…
Read more…

Portola Pharmaceuticals: Initiating Coverage with a Buy (PTLA, $40.05)

 Overview of Report
I am initiating coverage of Portola Pharmaceuticals with a Buy and a 2021 price target of $426.This is…
Read more…